Table 3.
TRAIL-receptor agonists
| Company | Treatment | Developmental stage |
|---|---|---|
| HGS | HGS-ETR1 (anti-TRAIL-Rl mAb) | Phase II completed: NHL, colorectal cancer, NSCLC |
| HGS-ETR1 + Paclitaxel + Carboplatin | Phase Ib: advanced solid tumors | |
| HGS-ETR1 + Gemcitabine + Cisplatin | Phase Ib: advanced solid tumors | |
| HGS-ETR1 + Bortezomib | Phase II: advanced multiple myeloma | |
| HGS-ETR2 (anti-TRAIL-R2 mAb) | Phase I: advanced solid tumors | |
| HGS-ETR2 + Chemotherapy | Phase Ib: advanced solid tumors | |
| HGS-TR2J (anti-TRAIL-R2 mAb) | Phase I: advanced solid tumors | |
| Daiichi Sankyo Inc. | TRA-8 (anti-TRAIL-R2) | Phase I: advanced solid tumors and lymphomas |
| CS-1008 (humanized version of TRA-8) | Phase I | |
| Novartis | LBY135 (anti-TRAIL-R2) | Phase I/II: advanced solid tumors |
| LBY135 + Capecitabine | Phase I/II: advanced solid tumors (recruiting since 2006) | |
| Genentech | Apomab (anti-TRAIL-R2) | Phase I/II: advanced solid tumors |
| Apomab + Avastin | Phase II: advanced solid tumors (initiated in 2007) | |
| Amgen | AMG655 (anti-TRAIL-R2) | Phase I: NSCLC, colorectal cancer (initiated in 2005) |
| Genentech/Amgen | Apo2L/TRAlL (soluble) | Phase Ib |
| Apo2L/TRAIL + Rituximab | Phase Ib/II: NHL (recruiting since 2006) | |
| Ad5-TRAIL | Phase Ia: organ-confined prostate cancer |